Brilliant Violet 421™ anti-human CD134 (OX40)

Antibodies Single
Sony
Ber-ACT35 (ACT35)
Flow Cytometry
Mouse IgG1, κ
Human
HTLV 1-transformed HUT 102 cells
2350070

Description

CD134, also known as OX40 and TNFRSF4, is a 50 kD type I transmembrane glycoprotein. It is a member of the TNF receptor family. OX40 is expressed on activated T lymphocytes including Th1, Th2, Th17, and Treg cells. The interaction of OX40 with OX40L results in B cell proliferation and antibody secretion, regulation of primary T cell expansion, and T cell survival. OX40 influences the size of the T cell memory pool and regulation of CD4+ T cell tolerance.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Latza U, et al. 1994. Eur. J. Immunol. 24:677. (WB, IP)
2. Durkop H, et al. 1995. Brit. J. Haematol. 91:927. (IHC)
3. Durkop H, et al. 1997. Brit. J. Haematol. 98:863. (IHC)
4. Willett B, et al. 2007. J. Virol. 81:9665. (ELISA)
5. Li M and Zhang Y. et al. 2005. Cell. Mol. Immunol. 2:467. (FA)
6. Gloviczki ML, et al. 2012. Clin. J. Am. Soc. Nephrol. 8:546. PubMed
7. Domingos PL, et al. 2012. An. Bras. Dermatol. 87:851. (IHC)